Business Context and Reporting Period
Company: SciSparc Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: January 2025 (Filing Date: January 7, 2025)
Principal Executive Offices: Tel Aviv, Israel
This filing reports a corporate development regarding a collaboration with Clearmind Medicine. The document incorporates a press release issued on January 6, 2025, concerning the publication of a European Patent Application for a psychedelic combination treatment targeting binge behavior.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a current report of a specific event and does not contain financial statements or quantitative financial data.
Material Changes
Intellectual Property Development: The Company announced the publication of a European Patent Application in collaboration with Clearmind Medicine. The patent covers a psychedelic combination treatment designed for binge behavior.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses solely on the strategic milestone of the patent publication. No financial guidance, future outlook, or specific risk factors are detailed within this specific document text.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the patent scope and collaboration terms.
- Review the Company's most recent Form 20-F or quarterly reports for current financial health, cash runway, and liquidity status.
- Confirm the status of the European Patent Application and any regulatory implications for the psychedelic treatment.
- Check for any subsequent filings that may update the financial impact of this collaboration.